| Title: |
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data |
| Authors: |
Strutton, David R; Farkouh, Raymond A; Rubin, Jaime L; McGarry, Lisa J; Loiacono, Paul M; Klugman, Keith P; Pelton, Steven I; Gilmore, Kristen E; Weinstein, Milton C |
| Publisher Information: |
BioMed Central Ltd. |
| Publication Year: |
2012 |
| Collection: |
BioMed Central |
| Subject Terms: |
Pneumococcal conjugate vaccine; Catch-up vaccination; Pneumococcal; PCV13; 13-valent |
| Description: |
Background Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%. Methods This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant. Results Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program. Conclusions Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
http://www.biomedcentral.com/1471-2334/12/175 |
| Availability: |
http://www.biomedcentral.com/1471-2334/12/175 |
| Rights: |
Copyright 2012 Strutton et al.; licensee BioMed Central Ltd. |
| Accession Number: |
edsbas.CE7C4FCA |
| Database: |
BASE |